Axsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($1.04) per share and revenue of $140.02 million for the quarter.

Axsome Therapeutics Stock Up 1.6%

AXSM opened at $103.02 on Friday. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.96 and a current ratio of 2.03. Axsome Therapeutics has a fifty-two week low of $72.21 and a fifty-two week high of $139.13. The firm’s fifty day moving average is $105.84 and its 200 day moving average is $110.41. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of -17.85 and a beta of 0.51.

Analyst Ratings Changes

A number of research analysts recently weighed in on AXSM shares. Jefferies Financial Group initiated coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They set a “buy” rating and a $200.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, June 10th. Wells Fargo & Company reiterated an “overweight” rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th. Finally, Oppenheimer initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, June 3rd. They issued an “outperform” rating and a $185.00 price target on the stock. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $172.33.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark Coleman sold 3,750 shares of the business’s stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the sale, the director directly owned 50,387 shares in the company, valued at $5,314,316.89. The trade was a 6.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Hunter R. Murdock sold 6,014 shares of the business’s stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $100.12, for a total transaction of $602,121.68. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock worth $9,834,215 in the last three months. Insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Caxton Associates LLP bought a new position in Axsome Therapeutics during the 1st quarter valued at about $307,000. Jones Financial Companies Lllp grew its holdings in Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after purchasing an additional 7,320 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,002 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after purchasing an additional 17,250 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after purchasing an additional 84,151 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.